Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400332 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 281
- Enrollment target
NCT03400332: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03400332 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 281 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (368% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03400332, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 281 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Primary Outcome
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately lif
Interventions
- OTHER Placebo
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG BMS-986253
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
What the finished NCT03400332 record still lists
NCT03400332 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (368% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03400332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03400332 about?
NCT03400332 is a clinical study titled "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers". The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
What is the current status of trial NCT03400332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2018-02-12. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT03400332?
The interventions under investigation include: Placebo (OTHER), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986253 (DRUG).
Who is sponsoring clinical trial NCT03400332?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03400332's enrollment target sits among peer trials
281 140th of 2000 higher than 1,860 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI